PUBLISHED ASSESSMENT

Guillain-Barré Syndrome and Flu Vaccine | Influenza (Flu) | CDC

This compact public record contains an assessment and source links. It does not contain article text, reader identity, browsing history, or private notes.

Historical provenance limit: this assessment has a recorded retrieval URL from before Beaconwright’s current publisher-verification boundary. It has not been reverified under the current boundary.

Open original article

The page’s central claims are strongly supported by large observational studies and appropriately framed as uncertain and involving a very small absolute risk. It provides useful infection and surveillance context but omits direct study citations, quantitative comparison with influenza-associated GBS, vaccine-type distinctions, and guidance for people with prior GBS. Authorship and monitoring systems are clear, while evidence selection and calculations remain inaccessible.

Evidence support

Strong (82/100)

Large population-based studies support the small absolute risk estimate and season-to-season inconsistency.
Studies consistently identify respiratory and gastrointestinal infections as stronger GBS risk factors than influenza vaccination.
Background incidence and increasing incidence with age are supported by epidemiological data.
The page does not directly cite evidence for each numerical and clinical claim.

Balance & context

Substantial (73/100)

The page states uncertainty, gives absolute rather than only relative risk, and explains that most GBS cases are unrelated to vaccines.
It identifies common infectious triggers and accurately cautions that VAERS reports generally cannot establish causation.
It omits quantitative comparison with GBS risk following influenza illness, relevant historical context, vaccine-type distinctions, and guidance for people with previous GBS.

Transparency

Substantial (64/100)

The responsible CDC center, publication date, monitoring agencies, and surveillance systems are clearly identified.
Uncertainty and VAERS limitations are explicitly described.
Underlying studies, calculations, evidence-selection methods, and conflicts or funding are not disclosed or directly linked.

Confidence and coverage

Confidence in this analysis: High confidence

Evidence coverage: Substantial coverage

Review was selective rather than a systematic evidence synthesis.
The page’s underlying references were not directly inspectable.
Evidence is largely observational because GBS is rare.

Multiple large primary studies directly address the central risk claim.
Evidence from different populations broadly supports the page’s cautious wording.
The main limitation concerns source transparency rather than lack of external evidence.

Sources considered

Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study — Estimated approximately 1.03 attributable GBS admissions per million vaccinations and substantially greater risk after influenza-related healthcare encounters.
Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections — Found no significant elevated vaccine risk after adjustment, while antecedent infections showed a strong association.
Seasonal influenza vaccine and Guillain-Barré syndrome: A self-controlled case series study — Found no significant post-vaccination increase across four seasons and markedly higher risk following respiratory or gastrointestinal infection.
Risk of Guillain-Barré syndrome after 2010–2011 influenza vaccination — Reported an elevated association and an attributable risk of two to five cases per million, illustrating variation between seasons and studies.
Guillain-Barré syndrome following influenza vaccination: A 15-year nationwide population-based case-control study — Found a slight short-term association but a very small population-attributable fraction.
FLUAD—US Package Insert — Provides clinically relevant precautions for people whose GBS occurred within six weeks of a previous influenza vaccine.

This assesses evidence and presentation; it is not an overall truth verdict.

Reassess

⚠ Paid reassessment incurs a charge. Opening this page does not start a run or incur a charge.

To request a new assessment, sign in to My library, watch this record, and select Request new assessment. Requests await separate approval and do not themselves start a paid run.

A new assessment may differ. Earlier published results remain in history.

Open My library

Assessment history

Published assessment trend

Available public snapshots only; this is not a count of all executions. Corrections may include earlier scores. Gaps mean not scored or not recorded. Different scores do not establish changed source evidence.

Evidence support — solid blueBalance & context — dashed purpleTransparency — dotted green

Reassess ⚠

Recorded public scores (0–100)
Date	Evidence support	Balance & context	Transparency
2026-09-12 (current)	82	73	64